591 related articles for article (PubMed ID: 24297940)
21. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F
J Clin Oncol; 1991 Jul; 9(7):1210-4. PubMed ID: 2045861
[TBL] [Abstract][Full Text] [Related]
22. [A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
Lou FD; Zhou Q; Meng FY
Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):146-8, 187. PubMed ID: 1395925
[TBL] [Abstract][Full Text] [Related]
23. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
[TBL] [Abstract][Full Text] [Related]
24. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results.
Wolff SN; Herzig RH; Fay JW; Phillips GL; Lazarus HM; Flexner JM; Stein RS; Greer JP; Cooper B; Herzig GP
J Clin Oncol; 1989 Sep; 7(9):1260-7. PubMed ID: 2769327
[TBL] [Abstract][Full Text] [Related]
25. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Dekker AW; van't Veer MB; Sizoo W; Haak HL; van der Lelie J; Ossenkoppele G; Huijgens PC; Schouten HC; Sonneveld P; Willemze R; Verdonck LF; van Putten WL; Löwenberg B
J Clin Oncol; 1997 Feb; 15(2):476-82. PubMed ID: 9053468
[TBL] [Abstract][Full Text] [Related]
26. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig WD; Fischer J; Aul HC; Vaupel HA; Kuse R; Zeile G
J Clin Oncol; 1985 Dec; 3(12):1583-9. PubMed ID: 3906048
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Schiller G; Gajewski J; Territo M; Nimer S; Lee M; Belin T; Champlin R
Blood; 1992 Dec; 80(12):2977-82. PubMed ID: 1467513
[TBL] [Abstract][Full Text] [Related]
28. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
[TBL] [Abstract][Full Text] [Related]
30. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
Bishop JF; Matthews JP; Young GA; Bradstock K; Lowenthal RM
Leuk Lymphoma; 1998 Jan; 28(3-4):315-27. PubMed ID: 9517503
[TBL] [Abstract][Full Text] [Related]
31. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.
Hann IM; Stevens RF; Goldstone AH; Rees JK; Wheatley K; Gray RG; Burnett AK
Blood; 1997 Apr; 89(7):2311-8. PubMed ID: 9116274
[TBL] [Abstract][Full Text] [Related]
32. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
Phillips GL; Reece DE; Shepherd JD; Barnett MJ; Brown RA; Frei-Lahr DA; Klingemann HG; Bolwell BJ; Spinelli JJ; Herzig RH
Blood; 1991 Apr; 77(7):1429-35. PubMed ID: 2009367
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
[TBL] [Abstract][Full Text] [Related]
34. Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia.
Wahlin A
Med Oncol Tumor Pharmacother; 1989; 6(3):199-205. PubMed ID: 2615524
[TBL] [Abstract][Full Text] [Related]
35. Improved survival for patients with acute myelogenous leukemia.
Mitus AJ; Miller KB; Schenkein DP; Ryan HF; Parsons SK; Wheeler C; Antin JH
J Clin Oncol; 1995 Mar; 13(3):560-9. PubMed ID: 7884416
[TBL] [Abstract][Full Text] [Related]
36. Etoposide in remission induction of adult acute myeloid leukemia.
Leoni F; Ciolli S; Patriarchi S; Morfini M; Rossi Ferrini P
Acta Haematol; 1990; 83(2):82-5. PubMed ID: 2106200
[TBL] [Abstract][Full Text] [Related]
37. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
[TBL] [Abstract][Full Text] [Related]
38. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
Fopp M; Fey MF; Bacchi M; Cavalli F; Gmuer J; Jacky E; Schmid L; Tichelli A; Tobler A; Tschopp L; Von Fliedner V; Gratwohl A
Ann Oncol; 1997 Mar; 8(3):251-7. PubMed ID: 9137794
[TBL] [Abstract][Full Text] [Related]
39. Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity.
Franco S; Khan T; Dinner S; Karmali R; Melody M
J Oncol Pharm Pract; 2024 Jul; 30(5):945-949. PubMed ID: 38509800
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission.
Schiller GJ; Nimer SD; Territo MC; Ho WG; Champlin RE; Gajewski JL
J Clin Oncol; 1992 Jan; 10(1):41-6. PubMed ID: 1727924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
